RPRX
$37.87
Royalty Pharma Plc Cl A
($.90)
(2.32%)
RPRX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  $0.59
Revenue:  $509.27 Mil
Wednesday
Nov 11
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, August 12, 2020

What do you expect when RPRX reports earnings?
Beat
Meet
Miss

Where is RPRX's stock price going from here?
Up
Flat
Down
Stock chart of RPRX
Analysts
Summary of analysts' recommendations for RPRX
Score
Grade
Pivots
Resistance
$40.63
$40.00
$39.39

$38.75

Support
$38.14
$37.51
$36.89
Tweet
Growth
Description
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.RepligenBio-TechneBioCryst Pharmaceuticals